

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

FDA HAS GREENLIGHTED PYRILUTAMIDE (KX-826)'S PHASE II CLINICAL TRIAL FOR ANDROGENETIC ALOPECIA IN THE US

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) is pleased to announce that the US Food and Drug Administration (the “**FDA**”) has greenlighted pyrilitamide (KX-826)’s phase II clinical trial (the “**Phase II Clinical Trial**”) for androgenetic alopecia (the “**AGA**”) to be conducted in the United States (the “**US**”).

The Phase II Clinical Trial is a randomised, double-blind, vehicle-controlled, parallel-group study, designed to evaluate the efficacy and safety of pyrilitamide in male subjects with AGA. The primary endpoint for the Phase II Clinical Trial is the change from baseline in non-vellus TAHC (Target Area Hair Counts) at Week 24 in comparison to vehicle. Meanwhile, patient dosing of pyrilitamide’s phase II clinical trial in China for AGA has been completed, the data of which is expected to read out in the third quarter of 2021.

Pyrilitamide is a topical androgen receptor (“**AR**”) antagonist with a specific target, which can inhibit the combination of AR and androgen in hair follicle sebaceous glands, thereby treating AGA and acne vulgaris.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that pyrilitamide will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, July 11, 2021

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Yaling Wu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* For identification purpose only